BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 31, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 1/28 cls
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Brean Murray Jonathan Aschoff Price target Buy -2% $82.34
Aschoff raised his target to $93 from $83 after updating his model and taking into account projected revenues out to 2014 for Soliris eculizumab and adding revenue for anti-kidney transplant rejection. The humanized mAb, which targets complement 5 (C5), is approved in Canada, EU, U.S. and Japan to treat paroxysmal nocturnal hemoglobinuria (PNH) and is in Phase II testing for atypical hemolytic uremic syndrome (aHUS) and anti-kidney transplant rejection.
Amgen Inc. (NASDAQ:AMGN) Barclays Capital Jim Birchenough Price target Overweight -3% $55.29
Birchenough reiterated his rating, but lowered his target to $72 from $76 on the company's 4Q10 earnings and program updates. Amgen reported 4Q10...

Read the full 880 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >